Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Baxter Announces Multiple Online Training Videos for Professionals Posted 04-12-2024
- Humana and Strive Health Expand Holistic Partnership to more Humana Members Posted 04-12-2024
- ASN and Home Dialysis University Collaboration to Increase Home Dialysis Posted 04-12-2024
- Telemedicine Can Help Grow Home Dialysis, Reduce Dropout, and Improve Outcomes Posted 03-15-2024